1. B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY. (5th April 2022) Authors: Rodriguez-Otero, P; Dholaria, B; Askari, E; Reece, D; van de Donk, N; Chari, A; Goldschmidt, H; Krishnan, A; Martin, T; Mateos, M; Morillo, D; Rodriguez, C; Rosinol, L; San-Miguel, J; Balari, A; Wäsch, R; Weisel, K; Verona, R; Lin, S; Prior, T Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?. (5th April 2022) Authors: Popat, R; Badros, A; Kumar, S; Rodriguez-Otero, P; Cohen, A; Manier, S; Voorhees, P; Gay, F; Rifkin, R; Martin, T; Chari, A; Weisel, K; Farooq, A; Jeng, B; Chng, W; Lee, H; Berdeja, J; Jadhav, V; Tosolini, A; Eliason, L Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗